CompletedNCT01575561
Lurasidone Added to Mood Stabilizers for Bipolarity
About this title
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
Read the official source — NCT01575561Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Dothan and 70 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 377
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Argentina, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01575561
- Official title
Show the full official title
A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedDothan, United States · Glendale, United States · Los Angeles, United States
57 more locations
- Oceanside, United States
- Palo Alto, United States
- San Francisco, United States
- Santa Ana, United States
- Stanford, United States
- Bradenton, United States
- Jacksonville, United States
- Miami Springs, United States
- Orlando, United States
- Atlanta, United States
- Terre Haute, United States
- Haverhill, United States
- St Louis, United States
- Rochester, United States
- Garlield Heights, United States
- Oklahoma City, United States
- Media, United States
- Lincoln, United States
- Charleston, United States
- Memphis, United States
- Dallas, United States
- Lake Jackson, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- Rosario, Argentina
- Rousse, Bulgaria
- Sofia, Bulgaria
- Santiago, Chile
- Brno - Mesto, Czechia
- Havířov, Czechia
- Písek, Czechia
- Prague, Czechia
- Přerov, Czechia
- Dijon, France
- Dole, France
- Nîmes, France
- Budapest, Hungary
- Sapporo, Japan
- Sakai, Japan
- Kumamoto, Japan
- Tokyo, Japan
- Toyama, Japan
- Gdynia, Poland
- Kielce, Poland
- Tuszyn, Poland
- Izhevsk, Russia
- Saint Petersburg, Russia
- Tomsk, Russia
- Velikiy Novgorod, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Rimavská Sobota, Slovakia
- Zlaté Moravce, Slovakia
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
